Abstract

21st Centuries Cures Act aims to fuel rapid innovation in drug development and patient access to innovative medical technologies while enhancing the ability to communicate value of innovation.

American Patients First Blueprint aims to modulate the rapid growth in healthcare costs of innovation by increasing competition, negotiation, and affordability.

Stakeholder implications of the 2 policies are significant across the US healthcare marketplace and in particular for HEOR professionals who can have major impact on the execution of both policies initiatives.